FDA Clearance Tracker · K232152
NerivioInfinity
Last checked: Nov 19, 2026Latest source record: Nov 8, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Nov 8, 2023
Substantially Equivalent
Time to decision
112 days
Received Jul 19, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K232152
- Device name
- NerivioInfinity
- Applicant
- Theranica Bioelectronics , Ltd.
- Applicant location
- Netanya, IL
- Received
- Jul 19, 2023
- Decided
- Nov 8, 2023
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 882.5899
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QGT. The earliest in FDA's data is DEN180059, decided May 20, 2019.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K232152
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Theranica Bioelectronics , Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Nerivio510(k)
K223169 · Decided Feb 6, 2023 · 118 days after receipt
Device type: Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT) · Neurology & Neurosurgery
- Nerivio, FGD000075-4.7510(k)
K203181 · Decided Jan 22, 2021 · 88 days after receipt
Device type: Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT) · Neurology & Neurosurgery
- Nerivio MigraNew device typeDe Novo
DEN180059 · Decided May 20, 2019 · 195 days after receipt
Device type: Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT) · Neurology & Neurosurgery
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.